What is Chardan Capital’s Estimate for SABS FY2025 Earnings?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Stock analysts at Chardan Capital lifted their FY2025 EPS estimates for SAB Biotherapeutics in a report released on Tuesday, April 1st. Chardan Capital analyst K. Nakae now expects that the company will post earnings per share of ($2.65) for the year, up from their previous forecast of ($3.64). Chardan Capital currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for SAB Biotherapeutics’ FY2025 earnings at ($2.65) EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of SAB Biotherapeutics in a report on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $11.40.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $1.13 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. The stock has a market capitalization of $10.50 million, a price-to-earnings ratio of -0.31 and a beta of 0.52. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $5.01. The stock’s 50-day simple moving average is $1.78 and its 200 day simple moving average is $2.78.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.07). The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.12 million. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

Institutional Trading of SAB Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp bought a new position in shares of SAB Biotherapeutics in the fourth quarter worth approximately $43,000. Diadema Partners LP bought a new position in shares of SAB Biotherapeutics in the 4th quarter worth $114,000. Geode Capital Management LLC raised its position in shares of SAB Biotherapeutics by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after buying an additional 12,692 shares in the last quarter. HB Wealth Management LLC lifted its holdings in shares of SAB Biotherapeutics by 118.6% during the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after acquiring an additional 128,800 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new position in SAB Biotherapeutics in the third quarter worth $52,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.